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Questions and answers on NPS 
 
In recent years, the market for amphetamine-type stimulants (ATS) has been 
characterized by the appearance of several new substances, which often have chemical 
and/or pharmacological properties similar to internationally controlled substances. 
Their variety has never been as great as it is now. 
 
What are NPS?  
New psychoactive substances (NPS) have been known in the market by terms such as 
‘designer drugs’, ‘legal highs’, ‘herbal highs’, ‘bath salts’, ‘research chemicals’ and 
‘laboratory reagents’. To promote clear terminology on this issue, UNODC only uses the 
term “new psychoactive substances (NPS)” which are defined as “substances of abuse, 
either in a pure form or a preparation, that are not controlled by the 1961 Single 
Convention on Narcotic Drugs or the 1971 Convention on Psychotropic Substances, but 
which may pose a public health threat”. The term ‘new’ does not necessarily refer to new 
inventions-- several NPS were first synthesized 40 years ago-- but to substances that have 
recently emerged on the market and which have not been scheduled under the drug 
control conventions. 
 
What are the risks of NPS?  
The use of NPS is often linked to health problems. NPS users have frequently been 
hospitalized with severe intoxications. There have also been a number of unexplained 
suicides with preceding use of synthetic cannabinoids (spice). In addition, substances like 
mephedrone, MDPV and 4-MA have been associated with fatalities. 
 
How widespread are NPS?  
According to the forthcoming UNODC report “The challenge of new psychoactive 
substances”, NPS have become a global phenomenon and all regions of the world have 
been affected by it. In a questionnaire that was distributed to Governments and drug 
analysis laboratories, respondents from 70 (out of 80) countries and territories 
reported the emergence of NPS. 
 
How many NPS are there?  
UNODC research found 251 substances, including ketamine, which were reported by 
Governments and laboratories around the world (see box for the categories of NPS 
frequently sold). The total number substances presently scheduled under the 1961 and 
1971 Conventions is 234. In February 2013, five new substances were reported by drug 
analysis laboratories. Technically, the number of potential derivatives is unlimited. As 
long as there is no global monitoring mechanism on such substances, information on 
them will remain inconsistent. 
 
What is the legal situation?  
NPS are not under international control. Many countries have established permanent 
control measures for some substances or issued temporary bans. Only a handful of NPS 
have been reviewed by the mechanism established under the 1961 and 1971 Conventions. 
Responses in this area are likely to be most effective if they are coordinated across 
countries and regions. NPS are also a challenge for prevention and treatment. Instead 
of moral panic, objective and credible information is needed. In this respect, it is 
particularly important to create risk awareness among young people. Prevention measures 
should also target experienced drug users. 
 
How can I find out more about NPS?  
In 2012, pursuant to a resolution from the Commission on Narcotic Drugs, UNODC 
reviewed the appearance of NPS in global markets and issued the first global overview of 
information on these substances and their use as well as a list of the substances reported 
to it in 2012. Future plans include the development of an online knowledge hub for NPS 
which will be accessible to policy-makers and experts to find out the most relevant facts 
about certain NPS. 
 
How is UNODC assisting Governments in this area?  
To assist Member States in their identification of NPS, UNODC plans to establish an 
Early Warning Advisory. Forensic information is essential and laboratories play a key 
role in identifying NPS. Accurate identification of NPS is a challenge and there is a need 
to improve information sharing on validated identification techniques. As part of 
addressing this challenge, UNODC has therefore been working on manuals on the 
identification of synthetic cannabinoids, synthetic cathinones and piperazines which are 
expected to be published in 2013. 
 
 
Categories of NPS sold in the market 
Synthetic cannabinoids – These substances produce effects similar to those of THC, the 
principal psychoactive component in cannabis. Synthetic cannabinoids are often laced 
onto herbal products and sold as spice, K2, Kronic, et cetera. 
 
Synthetic cathinones – These are analogues/derivatives of the internationally controlled 
substance cathinone, one of the active components of the khat plant. They generally have 
stimulant effects and include frequently reported NPS such as mephedrone and MDPV. 
 
Ketamine - A human and veterinary anesthetic which acts as a stimulant at low doses and 
a hallucinogen at high doses. It is one of the most widespread NPS in Asia. 
 
Phenethylamines – This group contains substances related to amphetamine and 
methamphetamine, and generally produces stimulant effects. However, modification of 
these compounds can lead to potent hallucinogens. 
 
Piperazines – These substances are frequently sold as ‘ecstasy’ due to their stimulant 
properties. The most commonly reported members of this group are benzylpiperazine 
(BZP) and mCPP. 
 
Plant-based substances- This group includes plants with psychoactive properties. The 
most frequently reported are: 
Kratom, a plant indigenous to South-East Asia that acts as a stimulant at low 
doses and sedative at high doses. 
Salvia divinorum, a plant indigenous to Mexico with hallucinogenic effects. 
Khat (Catha edulis), a plant native to the horn of Africa and the Arabian peninsula. 
The leaves of the plant are chewed, resulting in the release of the stimulants cathinone 
and cathine. 
 
Other substances – such as aminoindanes (stimulants), phencyclidine-type substances 
(hallucinogens) and tryptamines (hallucinogens). 
 
 
